Jubilant DraxImage is dedicated to providing radiopharmaceuticals for the diagnosis and treatment of a variety of diseases. We invite you to learn more about these areas and how our products are used by healthcare professionals to care for their patients.
Diseases of the lung span a broad range of health conditions, from the common flu to a life-threatening pulmonary embolism.
Nuclear medicine procedures are used by physicians to identify or evaluate certain lung conditions by assessing the movement of air into and out of the bronchi and bronchioles and the blood flow within the lungs.
Jubilant DraxImage is dedicated to providing the medical community with the radiopharmaceuticals that are essential to nuclear lung scans, such as macroaggregated albumin (MAA) and diethylene-triamine-pentaacetate (DTPA).
The sole supplier of MAA and DTPA in North America, Jubilant DraxImage is making significant investments in the nuclear medicine community to develop and maintain a robust supply chain for these vital products.
Learn more about pulmonary embolism and its diagnosis.
1. Gutte H, Mortensen J, Jensen CV, Johnbeck CB, von der Recke P, Petersen CL, et al. Detection of pulmonary embolism with combined ventilation-perfusion SPECT and low-dose CT: head-to-head comparison with multidetector CT angiography. J Nucl Med. 2009;50(12):1987–92. 2. DRAXIMAGE DTPA full Prescribing Information, Kirkland, QC, Dec. 2017 3. Bajc, M, et al. Ventilation/Perfusion SPECT for Diagnosis of Pulmonary Embolism and Other Diseases, Int J Mol Imaging. 2011; 2011: 682949. 4. Hur, S, et al. J Optimizing the Ventilation–Perfusion Lung Scan for Image Quality and Radiation Exposure. Nucl. Med. Technol. March 1, 2014 vol. 42 no. 1 51-54 5. Da Silva R, Shah M, Freeman LM. Ventilation-perfusion (V/Q) lung scintigraphy: a long journey to a renewed position of prominence in diagnosing pulmonary embolism. Clin Transl Imaging. 2014;2:369-378.